Tango Therapeutics (NASDAQ:TNGX) Announces Earnings Results, Beats Expectations By $0.02 EPS

Tango Therapeutics (NASDAQ:TNGX) issued its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.02, FiscalAI reports. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 60.80%.

Tango Therapeutics Trading Down 1.5%

Shares of TNGX traded down $0.25 during mid-day trading on Friday, hitting $16.58. The company’s stock had a trading volume of 3,756,230 shares, compared to its average volume of 3,354,465. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $17.63. The firm has a market capitalization of $2.23 billion, a P/E ratio of -17.83 and a beta of 1.76. The firm has a 50-day simple moving average of $11.70 and a 200 day simple moving average of $9.37.

Insiders Place Their Bets

In other news, Director Barbara Weber sold 30,519 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the completion of the transaction, the director owned 1,629,254 shares in the company, valued at $19,974,654.04. This trade represents a 1.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Daniella Beckman sold 10,317 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $126,486.42. Following the sale, the chief financial officer directly owned 184,297 shares in the company, valued at approximately $2,259,481.22. This represents a 5.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 113,633 shares of company stock worth $1,420,857. 7.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd boosted its stake in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after acquiring an additional 15,037 shares in the last quarter. Global Retirement Partners LLC purchased a new position in Tango Therapeutics in the 4th quarter valued at approximately $35,000. Legal & General Group Plc raised its holdings in Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Tango Therapeutics by 44.3% during the second quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock worth $49,000 after purchasing an additional 2,907 shares in the last quarter. Finally, Northeast Financial Consultants Inc acquired a new stake in Tango Therapeutics in the second quarter valued at $51,000. 78.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. B. Riley Financial raised their price target on Tango Therapeutics from $8.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Jefferies Financial Group reiterated a “buy” rating and issued a $18.00 target price on shares of Tango Therapeutics in a research note on Thursday. HC Wainwright upped their price target on Tango Therapeutics from $13.00 to $27.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus started coverage on Tango Therapeutics in a report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price target for the company. Finally, Wedbush boosted their price objective on shares of Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $18.25.

Trending Headlines about Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target sharply to $27 and reiterated a buy rating, implying ~61% upside from the referenced price. This is the most bullish analyst move and likely helped momentum. HC Wainwright Boost Ticker Report
• Positive Sentiment: Guggenheim raised its target to $20 with a buy rating (?19.5% upside), adding institutional credibility to the rally. Guggenheim Note
• Positive Sentiment: Wedbush boosted its target to $19 and moved to outperform (~13.5% upside), contributing to analyst-driven buying interest. Wedbush Note
• Positive Sentiment: Tango announced a codevelopment deal with Erasca that analysts and press flagged as a material commercial/clinical partnership — a key fundamental catalyst behind recent gains. Erasca Deal
• Positive Sentiment: A large investment firm purchased roughly $9.5M of TNGX shares (SEC filing), increasing institutional ownership and signaling conviction from a fund buyer. Institutional Purchase
• Neutral Sentiment: Q4 results: EPS of ($0.29) beat consensus ($0.31) by $0.02 — a modest beat, but still a cash?burning biotech profile. See the company release for details. Q4 Press Release
• Neutral Sentiment: Market commentary and “earnings to watch” pieces circulated ahead of/after the print; these amplified volatility but didn’t change fundamentals alone. Earnings to Watch
• Negative Sentiment: Despite the beat, Tango remains unprofitable with a negative net margin (~151%) and negative return on equity — underlying profitability risks remain for longer?term investors. Profitability Metrics

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.